Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
Status:
Recruiting
Trial end date:
2025-04-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the tolerability and safety of Xevinapant when added
to weekly cisplatin-based concurrent chemoradiotherapy (CRT) in the treatment of participants
with unresectable locally advanced squamous cell carcinoma of the head and neck, suitable for
definitive chemoradiotherapy.